The drugmaker Novo Nordisk is slated to report its second-quarter financial results early Wednesday, after shares plunged ...

By Christy Santhosh (Reuters) -Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United ...

Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by Eli Lilly as just one ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

With Novo Nordisk shedding double digits following its latest guidance cut, is this a chance to buy the dip or a warning sign ...

This maker of weight-loss drugs saw its share price zoom and then crash. The CEO has been replaced. The incoming boss will ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Novo Nordisk A/V (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

At least 26 patients have filed lawsuits in Marion County against Eli Lilly and Co. over its marketing of GLP-1 drugs ...

Hims & Hers Health stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of ...